UPLOAD Filing
60 DEGREES PHARMACEUTICALS, INC.
Date: June 13, 2025 · CIK: 0001946563 · Accession: 0000000000-25-006259
AI Filing Summary & Sentiment
Reasoning
Letter
Re: 60 Degrees Pharmaceuticals, Inc. Draft Registration Statement on Form S-1 Submitted June 6, 2025 CIK No. 0001946563 Dear Geoffrey S. Dow:
June 13, 2025
Geoffrey S. Dow President and Chief Executive Officer 60 Degrees Pharmaceuticals, Inc. 1025 Connecticut Avenue NW, Suite 1000 Washington, D.C. 20036
This is to advise you that we do not intend to review your registration statement.
We request that you publicly file your registration statement at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Ross D. Carmel, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> June 13, 2025 Geoffrey S. Dow President and Chief Executive Officer 60 Degrees Pharmaceuticals, Inc. 1025 Connecticut Avenue NW, Suite 1000 Washington, D.C. 20036 Re: 60 Degrees Pharmaceuticals, Inc. Draft Registration Statement on Form S-1 Submitted June 6, 2025 CIK No. 0001946563 Dear Geoffrey S. Dow: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Ross D. Carmel, Esq. </TEXT> </DOCUMENT>